Sanofi is set to classify Opella's business as discontinued operations following a transaction expected to close in Q2 2025, impacting its financial reporting. The company anticipates a low single-digit percentage growth in business EPS for 2024, excluding Opella, while maintaining its focus on shareholder returns and external growth opportunities. Sanofi continues to prioritize innovation in healthcare, aiming to enhance lives globally through scientific advancements.
Paris has approved a €15 billion sale of paracetamol manufacturer Opella to a US fund, securing guarantees for its continued operation and development in France. Despite political concerns over potential job losses and supply chain impacts, the government believes foreign investment is crucial for enhancing the country's pharmaceutical sector. An investment screening will follow the agreement, which involves Sanofi and the American buyer.
The French government has reached a tripartite agreement with Sanofi and the American investment fund CD&R for the sale of the Opella subsidiary, which markets Doliprane. The deal includes strong guarantees for maintaining production in France, with a commitment to produce 250 million boxes annually and significant penalties for non-compliance. CD&R will invest €70 million over five years, while the French state will hold a minority stake through Bpifrance to ensure governance and adherence to the agreed conditions.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.